Efficacy and safety of Ascoril in the management of cough--National Study Group report.
J Indian Med Assoc
;
2001 Feb; 99(2): 111, 114
Article
Dans Anglais
| IMSEAR
| ID: sea-101642
ABSTRACT
A total of 768 patients were recruited by 81 physicians and paediatricians all over the country in this National Study Group of 'Ascoril + Expectorant'. The results of this first large scale study of a cough formula indicates that 'Ascoril + Expectorant' is effective in controlling cough, breathlessness and decreasing the volume of sputum. No serious adverse events were noted. Ascoril was well accepted by the patients and its efficacy was rated very high by the physician. The National Study Group concludes that 'Ascoril + Expectorant' is highly effective in the management of cough associated with lower respiratory tract infection and COPDs.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Terbutaline
/
Bromhexine
/
Sujet âgé
/
Femelle
/
Humains
/
Mâle
/
Enfant
/
Enfant d'âge préscolaire
/
Adolescent
/
Résultat thérapeutique
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
J Indian Med Assoc
Année:
2001
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS